![](https://www.signifyresearch.net/wp-content/uploads/2024/07/SPI-MI-Tempus-IPO-wp-564x420.jpg)
Written by
![Phil Grainger headshot](https://www.signifyresearch.net/wp-content/uploads/2023/12/Phil-Grainger-150x150.jpg)
Phil Grainger
![Imogen Fitt headshot](https://www.signifyresearch.net/wp-content/uploads/2023/12/Signify-Imogen_F-Profile-@2-150x150.png)
Imogen Fitt
In June, Tempus AI, Inc. completed its initial public offering on the Nasdaq Global Select Market, raising $410.7 million.
Why we have chosen this topic
- Tempus is a digital precision medicine company with a unique position in the healthtech market and role in imaging IT.
- This success poses questions about the direction of the company’s longer-term strategy and influence on the wider imaging ecosystem.
Why it matters
- The IPO indicates that competition in the clinical real-world data (cRWD) platform market is about to intensify.
- As Tempus also provides healthcare technology products like radiology AI and clinical pathway software, this news may also impact wider healthcare technology markets.
Read the full insight with a Signify Premium Insights - Healthcare IT subscription